{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:33:23Z","timestamp":1788878003573,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40258-025-00950-3","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T09:23:24Z","timestamp":1738920204000},"page":"479-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Utility Analysis of Genomic Profiling in Directing Targeted Therapy in Advanced NSCLC in Thailand"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-3495","authenticated-orcid":false,"given":"Saowalak","family":"Turongkaravee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4828-4412","authenticated-orcid":false,"given":"Surakit","family":"Nathisuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyanan","family":"Baisamut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6845","authenticated-orcid":false,"given":"Jennis","family":"Meanwatthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"950_CR1","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749\u201368.","DOI":"10.1001\/jamaoncol.2019.2996"},{"key":"950_CR2","doi-asserted-by":"crossref","unstructured":"Collaborators GBDRTC. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respir Med. 2021;9(9):1030-49.","DOI":"10.1016\/S2213-2600(21)00164-8"},{"issue":"2","key":"950_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41588-019-0569-6","volume":"52","author":"J Chen","year":"2020","unstructured":"Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020;52(2):177\u201386.","journal-title":"Nat Genet"},{"issue":"1","key":"950_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13073-015-0203-x","volume":"7","author":"J Gagan","year":"2015","unstructured":"Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med. 2015;7(1):80.","journal-title":"Genome Med."},{"issue":"12","key":"950_CR5","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","volume":"32","author":"DM Vega","year":"2021","unstructured":"Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. 2021;32(12):1626\u201336.","journal-title":"Ann Oncol"},{"issue":"1","key":"950_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.20892\/j.issn.2095-3941.2018.0055","volume":"16","author":"D Qin","year":"2019","unstructured":"Qin D. Next-generation sequencing and its clinical application. Cancer Biol Med. 2019;16(1):4\u201310.","journal-title":"Cancer Biol Med"},{"key":"950_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100487","volume":"25","author":"R Colomer","year":"2020","unstructured":"Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020;25: 100487.","journal-title":"EClinicalMedicine."},{"key":"950_CR8","doi-asserted-by":"crossref","unstructured":"Aisner D, Sholl LM, Berry LD, Haura EB, Ramalingam SS, Glisson BS, et al. Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. American Society of Clinical Oncology; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.11510"},{"issue":"19","key":"950_CR9","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998\u20132006.","journal-title":"JAMA"},{"issue":"1","key":"950_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","volume":"8","author":"TL Stockley","year":"2016","unstructured":"Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT\/COMPACT trial. Genome Med. 2016;8(1):109.","journal-title":"Genome Med."},{"key":"950_CR11","unstructured":"NCCN Guideline Non-small cell lung cancer v.7 2021. [cited 2021 22 December]; https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines"},{"issue":"7","key":"950_CR12","first-page":"649","volume":"30","author":"IM Abbass","year":"2024","unstructured":"Abbass IM, Sheinson DM, Shah A, Gondos A, Ogale S. Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non-small cell lung cancer. J Manag Care Spec Pharm. 2024;30(7):649\u201359.","journal-title":"J Manag Care Spec Pharm"},{"key":"950_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00546","volume":"7","author":"E Arriola","year":"2023","unstructured":"Arriola E, Bernab\u00e9 R, Campelo RG, Biscuola M, Enguita AB, L\u00f3pez-R\u00edos F, et al. Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non-small-cell lung cancer from the perspective of Spanish reference centers. JCO Precis Oncol. 2023;7: e2200546.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"950_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/14737167.2022.2078310","volume":"22","author":"E de Alava","year":"2022","unstructured":"de Alava E, Pareja MJ, Carcedo D, Arrabal N, Garc\u00eda JF, Bernab\u00e9-Caro R. Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2022;22(6):1033\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"950_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00002","volume":"3","author":"L Steuten","year":"2019","unstructured":"Steuten L, Goulart B, Meropol NJ, Pritchard D, Ramsey SD. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. JCO Clin Cancer Inform. 2019;3:1\u201310.","journal-title":"JCO Clin Cancer Inform."},{"key":"950_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","volume":"139","author":"AC Tan","year":"2020","unstructured":"Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer. 2020;139:207\u201315.","journal-title":"Lung Cancer"},{"issue":"8","key":"950_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","volume":"24","author":"D Zou","year":"2022","unstructured":"Zou D, Ye W, Hess LM, Bhandari NR, Ale-Ali A, Foster J, et al. Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States. J Mol Diagn. 2022;24(8):901\u201314.","journal-title":"J Mol Diagn"},{"issue":"1","key":"950_CR18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1186\/s12885-020-07240-2","volume":"20","author":"L Schluckebier","year":"2020","unstructured":"Schluckebier L, Caetano R, Garay OU, Montenegro GT, Custodio M, Aran V, et al. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20(1):875.","journal-title":"BMC Cancer"},{"issue":"4","key":"950_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/ajco.13339","volume":"16","author":"DS Tan","year":"2020","unstructured":"Tan DS, Tan DS, Tan IBH, Yan B, Choo SP, Chng WJ, et al. Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. Asia Pac J Clin Oncol. 2020;16(4):222\u201331.","journal-title":"Asia Pac J Clin Oncol"},{"key":"950_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00421","volume":"8","author":"A Mathew","year":"2022","unstructured":"Mathew A, Joseph S, Boby J, Benny S, Veedu J, Rajappa S, et al. Clinical benefit of comprehensive genomic profiling for advanced cancers in India. JCO Glob Oncol. 2022;8: e2100421.","journal-title":"JCO Glob Oncol."},{"key":"950_CR21","doi-asserted-by":"crossref","unstructured":"Calvayrac O, Pradines A, Pons E, Mazieres J, Guibert N. Molecular biomarkers for lung adenocarcinoma. Eur Respir J. 2017;49(4).","DOI":"10.1183\/13993003.01734-2016"},{"issue":"27","key":"950_CR22","doi-asserted-by":"publisher","first-page":"41691","DOI":"10.18632\/oncotarget.9541","volume":"7","author":"D Zheng","year":"2016","unstructured":"Zheng D, Wang R, Ye T, Yu S, Hu H, Shen X, et al. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget. 2016;7(27):41691\u2013702.","journal-title":"Oncotarget"},{"issue":"1","key":"950_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/annonc\/mdx629","volume":"29","author":"KM Kerr","year":"2018","unstructured":"Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, et al. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Ann Oncol. 2018;29(1):200\u20138.","journal-title":"Ann Oncol"},{"issue":"20","key":"950_CR24","first-page":"6232","volume":"25","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Jeong GH, Li H, Kim MS, Kim JS, Park SJ, et al. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(20):6232\u201344.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"950_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.lungcan.2018.04.003","volume":"120","author":"C Limwattananon","year":"2018","unstructured":"Limwattananon C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand. Lung Cancer. 2018;120:91\u20137.","journal-title":"Lung Cancer"},{"key":"950_CR26","doi-asserted-by":"crossref","unstructured":"Kamps R, Brand\u00e3o RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2).","DOI":"10.3390\/ijms18020308"},{"issue":"4","key":"950_CR27","first-page":"177","volume":"32","author":"C Meldrum","year":"2011","unstructured":"Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011;32(4):177.","journal-title":"Clin Biochem Rev"},{"key":"950_CR28","unstructured":"Guidelines for Health Technology Assessment in Thailand (Second Edition). Nonthaburi 2013."},{"issue":"2","key":"950_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229179","volume":"15","author":"J Elliott","year":"2020","unstructured":"Elliott J, Bai Z, Hsieh SC, Kelly SE, Chen L, Skidmore B, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PLoS ONE. 2020;15(2): e0229179.","journal-title":"PLoS ONE"},{"issue":"6","key":"950_CR30","doi-asserted-by":"publisher","first-page":"35770","DOI":"10.1038\/srep35770","volume":"27","author":"S Ye","year":"2016","unstructured":"Ye S, Li J, Hao K, Yan J, Zhou H. The efficacy and risk profile of c-Met inhibitors in non-small cell lung cancer: a meta-analysis. Sci Rep. 2016;27(6):35770.","journal-title":"Sci Rep"},{"issue":"1","key":"950_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12916-021-02082-6","volume":"19","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang X, Zhang R, Xu Q, Yang H, Lizaso A, et al. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. BMC Med. 2021;19(1):206.","journal-title":"BMC Med"},{"issue":"13","key":"950_CR32","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207\u201317.","journal-title":"N Engl J Med"},{"key":"950_CR33","doi-asserted-by":"crossref","unstructured":"Perrone F, Mazzaschi G, Minari R, Verze M, Azzoni C, Bottarelli L, et al. Multicenter observational study on metastatic non-small cell lung cancer harboring BRAF mutations: focus on clinical characteristics and treatment outcome of V600E and Non-V600E subgroups. Cancers (Basel). 2022;14(8).","DOI":"10.3390\/cancers14082019"},{"key":"950_CR34","doi-asserted-by":"crossref","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381.","DOI":"10.1056\/NEJMoa2103695"},{"key":"950_CR35","unstructured":"Commerce; Mo. Report for Consumer Price Index of Thailand. [cited 2024 July]; http:\/\/www.indexpr.moc.go.th\/price_present\/TableIndexG_region.asp?table_name=cpig_index_country&province_code=5&type_code=g&check_f=i&year_base=2562&nyear=2552"},{"key":"950_CR36","unstructured":"Ministry of Public Health. Drug and medical supply information center. [cited 2024 July]; http:\/\/dmsic.moph.go.th\/index\/drugsearch\/1"},{"issue":"5","key":"950_CR37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/03007995.2017.1297929","volume":"33","author":"S Thongprasert","year":"2017","unstructured":"Thongprasert S, Permsuwan U. Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand. Curr Med Res Opin. 2017;33(5):955\u201361.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 5","key":"950_CR38","first-page":"S127","volume":"97","author":"A Riewpaiboon","year":"2014","unstructured":"Riewpaiboon A. Standard cost lists for health economic evaluation in Thailand. J Med Assoc Thai. 2014;97(Suppl 5):S127\u201334.","journal-title":"J Med Assoc Thai"},{"key":"950_CR39","doi-asserted-by":"crossref","unstructured":"Stein MK, Oluoha O, Patel K, VanderWalde A. Precision medicine in oncology: a review of multi-tumor actionable molecular targets with an emphasis on non-small cell lung cancer. J Pers Med. 2021;11(6).","DOI":"10.3390\/jpm11060518"},{"key":"950_CR40","unstructured":"Ministry of Public Health. Drug And Medical Supply Information Cente. [cited 2021 1 September]; http:\/\/dmsic.moph.go.th\/index\/drugsearch\/1"},{"issue":"1","key":"950_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1743-7563.2012.01528.x","volume":"8","author":"S Thongprasert","year":"2012","unstructured":"Thongprasert S, Tinmanee S, Permsuwan U. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective. Asia Pac J Clin Oncol. 2012;8(1):53\u201361.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"950_CR42","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195\u2013203.","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-00950-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T13:36:13Z","timestamp":1746452173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-00950-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-00950-3","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"19 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Open access funding provided by Mahidol University. This research received no external funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/Support"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The Research Ethics Committee (MU-DT\/PY-IRB) at Mahidol University has reviewed this study and determined that it does not involve human subjects research, as it utilizes data obtained from publicly available, published research articles.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are contained within the electronic supplementary material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not available.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ST, TB, and JM were involved in the conception and design, analysis, interpretation of the data, and\u00a0drafting of the paper. SN was involved in analyzing and interpreting the data, drafting the paper, and revising it critically for intellectual content. All authors granted the final approval of the version to be published and agreed to be accountable for all aspects of the work.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}